STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
about
The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyondThe PIM kinases in hematological cancersAdditive effects of cherlerythrine chloride combination with erlotinib in human non-small cell lung cancer cells.Signal integration and gene induction by a functionally distinct STAT3 phosphoform.Cucurbitacin I induces protective autophagy in glioblastoma in vitro and in vivoIntratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma.Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivoEmerging translational approaches to target STAT3 signalling and its impact on vascular diseaseMolecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathwayHigh-fat-diet-induced obesity causes an inflammatory and tumor-promoting microenvironment in the rat kidneyWP1066 suppresses macrophage cell death induced by inflammasome agonists independently of its inhibitory effect on STAT3.Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling.Update on JAK2 Inhibitors in Myeloproliferative NeoplasmAndrogen-STAT3 activation may contribute to gender disparity in human simply renal cystsInhibition of Signal Transducer and Activator of Transcription 3 (STAT3) reduces neonatal hypoxic-ischaemic brain damageFirst-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells.JAK/STAT regulation of Aspergillus fumigatus corneal infections and IL-6/23-stimulated neutrophil, IL-17, elastase, and MMP9 activity.Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks.STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cellsTargeted therapy for renal cell carcinoma: The next lap.Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.Progress of molecular targeted therapies for advanced renal cell carcinoma.Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature.The Role of STAT3 in Non-Small Cell Lung Cancer.Emerging strategies for cancer immunoprevention.Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma.Inhibition of glycogen synthase kinase 3 beta (GSK3β) suppresses the progression of esophageal squamous cell carcinoma by modifying STAT3 activity.Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma.CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis.Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies.Curcumin protects against acute renal injury by suppressing JAK2/STAT3 pathway in severe acute pancreatitis in rats
P2860
Q26851645-C824E0AA-8E9D-45F8-9C8F-92C0C4B02A7AQ28258028-E3F3585F-8E1C-4731-BDFC-1F0D98CD3D67Q33554429-7D29A58B-4E5D-4081-A0B7-5FC5CD21E657Q33602531-0AF0CE37-93B6-4D0A-AE03-5E7B7E50BF03Q33675791-BA285223-EC24-434D-B70F-3853B78F1A01Q34393758-CF108B2D-DDE1-4315-A1B4-98F17F4EF7A7Q35064011-33EBB6F1-F6B7-427A-BAA3-E7116AA40BEEQ35164307-FA163252-0370-45BF-B37C-EB36C94EFCE1Q35580177-295AE97B-E96B-466B-A1D5-3DF7BF9DBF92Q35587235-BF266690-40BD-453D-9812-DA97A325294FQ35685245-107A3320-B5E5-4BBC-A066-46CE996C497AQ35687115-3EEB2530-812F-486C-AE20-CA430A2D9957Q36179956-F8D9D2A8-0B8C-468D-B86E-CFB4BC86B3D3Q36236160-A298C750-7225-4518-90C3-C910F8F422C7Q36243367-D765F49C-41AD-4673-BAE8-A5D0F761BBDFQ36612569-4E978C01-CC4D-434F-9E57-CBBF42DB01B2Q36712022-BAC384AB-C3EC-4EFB-860A-0CAC01434CD3Q36832777-92112A06-3C59-4500-9513-1DC79F5BD548Q36890491-D272B61B-3C96-4A7B-BAAB-854032433AC2Q37022338-F6E6983B-D3BB-4ACA-B6A8-20B63C5125E8Q37098061-7198EFD2-5F83-4345-8685-044AD2B11242Q37113973-C3805DE5-6656-4CE6-AE8C-6C5F68713A13Q37357080-21CD046C-A2AC-4462-AB73-5FE1E9017DBBQ37404757-F39F8F43-000A-4831-A8B4-7F0D4A186EA2Q37702529-2597AEE9-43EE-4AD3-8D0B-8CA84CD38A67Q37869903-F86D9C73-A064-4BD6-8CA3-052155AE6DAAQ38149133-9480D167-EE4F-4D87-A3DD-1BDC83C29B4AQ38153283-B6CE8159-C132-4A44-979C-B910014228A3Q38179031-021EC496-1797-4EC4-A257-2B9733B5EFBDQ38199934-7DE41F3B-094A-4B9E-ADFB-C2307F0C6DC0Q38585850-887ACC42-36C5-46CB-8E54-A23F49053B08Q38706677-191F470B-BB73-45C8-AA86-06FF2B745EADQ38748837-32756771-1523-4CF0-A1F3-83C75836738DQ38800562-826A20DD-A148-465A-B44D-CE883813E9BFQ38866915-D04F07DF-6549-499A-A5DD-0C5326D0E52DQ38953038-E4D3B162-6F2E-411D-AA30-BB8292F1363FQ39024059-2704BD2F-DEE2-434F-8FB8-712795DC44C6Q39186157-60C698EE-5B36-4BC1-8BC6-39A5E5D63286Q39521993-C677598E-9FD7-48D2-9E46-5E461EA3E716Q41116521-820973AC-8676-41EC-8007-EC81C4A21EB1
P2860
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
@ast
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
@en
type
label
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
@ast
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
@en
prefLabel
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
@ast
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
@en
P2093
P2860
P356
P1476
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.
@en
P2093
A Horiguchi
M Hayakawa
M Sumitomo
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605691
P407
P577
2010-05-11T00:00:00Z
P5875
P6179
1012090202